Mylotarg and Agranulocytosis - a phase IV clinical study of FDA data

Summary:

Agranulocytosis is found among people who take Mylotarg, especially for people who are male, 60+ old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Mylotarg and have Agranulocytosis. It is created by eHealthMe based on reports of 3,967 people who have side effects when taking Mylotarg from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 20, 2023

3,967 people reported to have side effects when taking Mylotarg.
Among them, 278 people (7.01%) have Agranulocytosis.

What is Mylotarg?

Mylotarg has active ingredients of gemtuzumab ozogamicin. eHealthMe is studying from 3,968 Mylotarg users for its effectiveness, alternative drugs and more.

What is Agranulocytosis?

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection) is found to be associated with 3,194 drugs and 3,408 conditions by eHealthMe.

Number of Mylotarg and Agranulocytosis reports submitted per year:

* Approximation only. Some reports may have incomplete information.

Do you take Mylotarg and have Agranulocytosis?

Check whether Agranulocytosis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Fasullo, S., Davì, S., Cosenza, G., Di Franco, F., La Manna, N., Giubilato, A., ... & Maringhini, G. , "Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature", Journal of thrombosis and thrombolysis, 2018 Jan .

Related studies

How severe was Agranulocytosis and when was it recovered:

Agranulocytosis in Mylotarg

Expand to all the drugs that have ingredients of gemtuzumab ozogamicin:

Agranulocytosis and drugs with ingredients of gemtuzumab ozogamicin (359 reports)

Alternative drugs to, pros and cons of Mylotarg:

Mylotarg (3,968 reports)

Common Mylotarg side effects:

Browse all side effects of Mylotarg:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Agranulocytosis treatments and more:

Agranulocytosis (180,980 reports)

COVID vaccines that are related to Agranulocytosis:

Common drugs associated with Agranulocytosis:

All the drugs that are associated with Agranulocytosis:

Agranulocytosis (3,194 drugs)

Common conditions associated with Agranulocytosis:

Multiple myeloma: 9,913 reports
Breast cancer: 5,558 reports
High blood pressure: 5,100 reports
Schizophrenia: 4,907 reports
Non-hodgkin's lymphoma: 3,585 reports

All the conditions that are associated with Agranulocytosis:

Agranulocytosis (3,408 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on gemtuzumab ozogamicin (the active ingredients of Mylotarg) and Mylotarg (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.